Phase 2 N=383 An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Change in Hemoglobin A1c (A1C) From Baseline (NGSP Value) — -0.61; -0.80; -0.79; -0.88 percent HbA1C
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=49 Outpatient Pump Shutoff Pilot Feasibility and Efficacy Study
Type 1 Diabetes
Primary: Hypoglycemia Outcome: Percentage of Nights With Sensor Glucose Value </=60 mg/dl — 21; 33 percentage of nights — p=<0.001
Phase 2 N=29 Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer
Bladder Cancer
Primary: Percentage of Patients With Complete Pathologic Response After 3 Cycles of Treatment — 27.3 percentage of patients
Phase 2 N=42 Phase II Trial of Pentostatin and Targeted Busulfan
Hematologic Malignancies
Primary: Incidence of Greater Than or Equal to 50% Donor Chimerism — 100 percentage of participants
Phase 2 N=16 Digoxin for Recurrent Prostate Cancer
Prostate Cancer
Primary: Rate of Positive PSADT Outcome — 5 participants
Phase 2 N=40 Cox-2 Inhibition in Radiation-induced Oral Mucositis
Oral Mucositis
Primary: Clinical Oral Mucosal Injury Score at Cumulative Radiation Dose of 5000 cGy — 1.42; 1.36 units on a scale
Phase 2 N=198 A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.
Asthma
Primary: Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-24 Hours (AUC 0-24h) Response at the End of Each Treatment Period — -0.004; 0.135; 0.178; 0.201 Liter…
Phase 2 N=40 Safety and Effectiveness of Arcuate Incisions Performed With the iFS Femtosecond Laser System
Corneal Astigmatism
Primary: Reduction of Astigmatism — -0.75; -0.88 diopter
Phase 2 N=30 Clevidipine Bolus Administration in the Treatment of Hypertensive Patients Undergoing Cardiac Surgery (SPRINT)
Hypertension
Primary: The Mean Maximum Absolute Change in Systolic Blood Pressure From Baseline Within 15 Minutes From the First Bolus Dose of Clevidipine (Treatment Period 1, Bolus 1…
Phase 2 N=63 Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias
Chronic Myelogenous Leukemia
Primary: Number of Participants With Dose-Limiting Toxicity (DLT) - Part 1 — 1; 1; 0 Participants
Phase 2 N=100 Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT)
Graft-Versus-Host Disease
Primary: The Percentage of Participants Experiencing Acute GVHD After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) — 45; 18 percentage of participants
Phase 2 N=327 A Study to Evaluate the Effectiveness and Safety of MEDI-528 in Adults
Asthma
Primary: Change at Day 92 From Baseline in Mean Asthma Control Questionnaire (ACQ) Scores (Intent-toTreat Analysis) — -1.23; -1.10; -1.26; -1.31 Scores on a scale — p=0.435
Phase 2 N=149 Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC
Transitional Cell Carcinoma · Bladder Cancer
Primary: Median Progression-Free Survival (PFS) — 2.56; 1.58 months — p=0.939
Phase 2 N=103 Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation
Chronic Myeloid Leukemia
Primary: Percentage of Participants Achieving an Overall Hematologic Response by Subpopulation and Total Population — 77.4; 55.0; 9.5; 59.2 percentage of participants
Phase 2 N=18 Evaluation of Reproducibility of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers
MALARIA · FEVER · Sweating Fever
Primary: Infection for P. Vivax — 11; 11; 9 days